Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

January 10, 2022

View Complete Issue Table of Contents 2019

Download PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related
Terms Hide Related
Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2022 Jan 10;64(1641):e1-5

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report

Objective(s)

Upon completion of this activity, the participant will be able to:

Discuss the 2021-2022 recommendations for antiviral treatment and prophylaxis of seasonal influenza.

Select a term to see related articles Antiviral drugs baloxavir FluMist influenza influenza vaccine Neuraminidase inhibitors oseltamivir peramivir Rapivab Relenza Tamiflu Xofluza zanamivir

Superseded by The Medical Letter "Comparison Chart: Antiviral Drugs for Influenza for 2023-2024 (online only)" - Issue 1689, November 13, 2023

View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.